Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423133 | 0.85 | KIF11 (0.47) | KIF11PDK2 | |
| SCHEMBL14819 | 0.74 | CTNNB1 (0.41) | KIF11 | |
| SCHEMBL19454304 | 0.74 | CYP1A2 (0.35) | PDK2 | |
| SCHEMBL21399749 | 0.73 | MMP12 (0.33) | PDK2 | |
| SCHEMBL2665687 | 0.72 | KIF11 (0.41) | KIF11 | |
| SCHEMBL12423983 | 0.70 | KIF11 (0.46) | KIF11 | |
| SCHEMBL2666535 | 0.69 | KIF11 (0.34) | KIF11 | |
| SCHEMBL14449368 | 0.69 | TRPA1 (0.31) | — | |
| SCHEMBL24701674 | 0.67 | KDM4E (0.40) | — | |
| SCHEMBL19563466 | 0.67 | KIF11 (0.53) | KIF11PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | CCNT1, CCNA1, CCND1 | KIF11 3728/4885PDK2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.